Hosi Medical Sanso Lifts FY2027 Forecast on Margin Recovery
Hosi Medical Sanso Co., Ltd. (TSE:7634), Japan’s leading medical gas supplier, reported full-year results for the fiscal year ended March 2026 marked by modest revenue growth offset by profit contraction, though management’s forward guidance signals a return to earnings expansion as cost pressures ease.
The company posted revenue of JPY 15.5bn, up 2.8% year-over-year, but operating profit declined 3.2% to JPY 1.92bn and net profit fell 6.2% to JPY 1.37bn. The divergence between revenue and profit growth reflects elevated energy and logistics costs that outpaced sales gains—a structural challenge facing the medical gas sector. However, the company maintained a robust operating margin of 12.4%, and management’s FY2027 guidance projects operating profit recovery of 3.2%, suggesting confidence in cost normalization and pricing adjustments ahead.
| Metric | FY2026 Actual | YoY Change |
|---|---|---|
| Revenue | JPY 15.5bn | +2.8% |
| Operating Profit | JPY 1.92bn | -3.2% |
| Ordinary Income | JPY 2.00bn | -2.5% |
| Net Profit | JPY 1.37bn | -6.2% |
| Operating Margin | 12.4% | — |
| Equity Ratio | 74.8% | Stable |
Business Overview
Hosi Medical Sanso is Japan’s largest medical gas supplier, operating dual revenue pillars: hospital-based medical gas distribution and home-care oxygen and equipment rental services. The company also provides care equipment rental and sales, positioning it to benefit from Japan’s structural shift toward home-based medical care as the population ages. Its market leadership is reflected in consistent supply relationships with hospitals and clinics nationwide, where reliability and regulatory compliance command premium positioning over price competition.
Results Analysis
The FY2026 earnings reveal a company navigating a temporary cost-inflation cycle rather than facing structural demand weakness. Revenue growth of 2.8% confirms stable underlying demand for medical gases—oxygen and carbon dioxide output remained “steady,” according to management—but this gain was overwhelmed by surging energy and transportation expenses. The 3.2% decline in operating profit despite positive revenue growth is characteristic of capital-intensive, commodity-adjacent businesses where input cost volatility directly compresses margins.
The more pronounced 6.2% decline in net profit versus the 3.2% operating profit drop signals additional headwinds from non-operating items, likely including higher interest expenses or unfavorable foreign exchange movements, though management did not flag extraordinary charges. This suggests financial leverage or yen weakness created secondary margin pressure.
On the positive side, the company’s equity ratio of 74.8% remains exceptionally strong, indicating minimal reliance on debt financing and substantial financial flexibility. Operating cash flow improved to JPY 2.48bn from JPY 2.19bn, demonstrating that underlying cash generation remains healthy despite reported profit contraction. Management’s decision to increase annual dividends to JPY 90 per share from JPY 70—a 28.6% increase—reflects confidence in earnings recovery and signals that the profit decline is viewed as cyclical rather than structural.
The 12.4% operating margin, while down from prior-year levels, substantially exceeds typical margins in medical device and healthcare services sectors, underscoring Hosi Medical Sanso’s competitive moat and pricing power within its regulated market.
Next Year Guidance
| Metric | FY2027 Forecast | YoY Change |
|---|---|---|
| Revenue | JPY 15.66bn | +0.9% |
| Operating Profit | JPY 1.98bn | +3.2% |
| Ordinary Income | JPY 2.06bn | +3.0% |
| Net Profit | JPY 1.40bn | +2.0% |
Management’s FY2027 guidance is notably conservative, projecting revenue growth of only 0.9% while targeting operating profit expansion of 3.2%—a clear signal of anticipated margin recovery. This implies operating margin improvement to approximately 12.6%, suggesting that energy cost inflation is expected to moderate and pricing adjustments to take hold. The guidance reflects realistic expectations: modest top-line growth reflecting Japan’s mature healthcare market, coupled with operational leverage and cost normalization driving profit expansion. This is a credible, achievable target rather than an aggressive forecast.
What to Watch
Cost Pass-Through Execution: The critical variable for FY2027 will be management’s ability to implement price increases for medical gas supply contracts without losing volume. Hospital procurement is price-sensitive but supply-critical; success here will validate the margin recovery thesis.
Home-Care Segment Momentum: As Japan’s healthcare system increasingly shifts toward outpatient and home-based care, Hosi Medical Sanso’s home-care oxygen rental and equipment business should become a faster-growing profit contributor. Monitor segment-level disclosure for acceleration signals.
Capital Allocation and M&A: With strong cash generation, high equity ratios, and elevated dividend payouts, the company has capacity for strategic acquisitions in adjacent care services. Any material M&A would signal management’s growth strategy beyond organic expansion in a mature market.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.